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Abstract
The baseline value of neutrophil to lymphocyte ratio (NLR) has been found to be prognostic
in patients with metastatic castration resistant prostate cancer (CRPC). We evaluated the
impact of baseline NLR and its change in patients receiving enzalutamide. We included
consecutive metastatic CRPC patients treated with enzalutamide after docetaxel and stud-
ies the change of NLR (>3 vs3) after week 4 and 12 weeks. Progression-free survival
(PFS), overall survival (OS) and their 95% Confidence Intervals (95% CI) were estimated by
the Kaplan-Meier method and compared with the log-rank test. The impact of NLR on PFS
and OS was evaluated by Cox regression analyses and on prostate-specific antigen
response rates (PSA RR; PSA decline >50%) were evaluated by binary logistic regression.
Data collected on 193 patients from 9 centers were evaluated. Median age was 73.1 years
(range, 42.8–90.7). The median baseline NLR was 3.2. The median PFS was 3.2 months
(95% CI = 2.7–4.2) in patients with baseline NLR >3 and 7.4 months (95% CI = 5.5–9.7) in
those with NLR3, p < 0.0001. The median OS was 10.4 months (95% CI = 6.5–14.9) in
patients with baseline NLR >3 and 16.9 months (95% CI = 11.2–20.9) in those with baseline
NLR3, p < 0.0001. In multivariate analysis, changes in NLR at 4 weeks were significant
predictors of both PFS [hazard ratio (HR) 1.24, 95% confidence interval (95% CI) 1.07–
1.42, p = 0.003, and OS (HR 1.29, 95% CI 1.10–1.51, p = 0.001. A persistent NLR >3 during
treatment with enzalutamide seems to have both prognostic and predictive value in CRPC
patients.
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Introduction
Over the last decade, an increasing number of novel drugs for castration-resistant prostate can-
cer (CRPC), including cabazitaxel [1], abiraterone acetate [2, 3], enzalutamide [4, 5], sipuleucel-
T [6], and radium-223 [7], have changed the scenario of prostate cancer (PC) management.
These new agents have led to longer survival and improved quality of life of these patients. How-
ever, the identification of prognostic and predictive factors has also become necessary to help
physicians in their choice of treatment and sequencing of drugs. The growing knowledge of
tumor biology and/or tumor–host interaction is giving rise to the development of novel circulat-
ing biomarkers that facilitate patient risk stratification and the prediction of treatment benefit.
Inflammation, given its important role in the modulation of the cancer microenvironment
has emerged over the last few years as a key pathogenic mechanism for carcinogenesis and
tumor progression [8–10]. The inflammatory response is detectable in peripheral blood as neu-
trophilia and/or lymphopenia [9]. Consequently, neutrophil to lymphocyte ratio (NLR) has
been proposed as a simple circulating indicator of cancer-related inflammation [10], and has
been shown to have prognostic significance in several tumor types [11]. In PC patients, NLR
has been evaluated in various disease setting and in association with different drugs, including
some new hormonal agents [12–16].
This study assessed the possible predictive and prognostic role of NLR and its modification
in CRPC patients treated with enzalutamide, a potent androgen receptor antagonist that inhib-
its nuclear translocation and DNA binding [17]. Enzalutamide is approved for use in meta-
static CRPC patients previously treated with docetaxel [4]. Unlike some other key drugs for
PC, enzalutamide is not co-administered with corticosteroids, which may alter NLR due to the
accelerated release of neutrophils from the bone marrow into the circulation [18, 19]. We
therefore reasoned that studying enzalutamide treated patients would be more informative
than studying the correlation between NLR and PC outcome in patients treated with drugs co-
administered with steroids, such as docetaxel, cabazitaxel, or abiraterone. In addition, we not
only considered NLR value at baseline, but also during treatment, in the hope that it might
shed more light on the impact of NLR on CRPC patients treated with enzalutamide.
Patients and Methods
Study patients
We retrospectively considered 193 consecutive patients with CRPC treated with enzalutamide
after docetaxel between August 2012 and December 2014 in a compassionate-use program in
six Italian hospitals (102 patients), or as standard treatment in three UK hospitals (91 patients).
The study protocol was approved by the Ethical Committee of Istituto Scientifico Romagnolo
per lo Studio e la Cura dei Tumori (I.R.S.T.). Written informed consent was obtained from all
patients. Selection criteria included histologically confirmed prostatic adenocarcinoma pro-
gressing on androgen deprivation therapy (ADT) and at least 1 prior chemotherapeutic regimen
including docetaxel every 3 weeks. Moreover, we considered evaluable for this analysis only
patients who received enzalutamide for at least 3–4 weeks. The cutoff values of NLR (>3 vs3)
were evaluated at baseline (pre-therapy NLR) and after 4 and 12 weeks (follow-up NLR).
Treatment and evaluation
Treatment consisted of enzalutamide 160 mg orally daily administered continuously until pro-
gressive disease (PD) or interruption for severe toxicity. The Prostate Cancer Clinical Trials
Working Group 2 (PCWG2) criteria were used to define response and progression [20]. All
recorded PSA test, full blood examinations, including a complete blood count, and scan results
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Abbreviations: ADT, androgen deprivation therapy;
BIC, Bayesian Information Criterion; CI, confidence
interval; CRPC, castration-resistant prostate cancer;
CT, computed tomography; CTCAE, Common
Terminology Criteria for Adverse Events; DNA,
Deoxyribonucleic acid; ECOG, Eastern Cooperative
Oncology Group; HR, hazard ratio; LDH, lactate
dehydrogenase; NLR, neutrophil to lymphocyte ratio;
nr, not reached; PSA, prostate-specific antigen; OS,
overall survival; PC, prostate cancer; PFS,
progression free survival; PCWG, Prostate Cancer
Working Group; PD, progressive disease; PSA,
Prostate-Specific Antigen; RECIST, Response
Evaluation Criteria in Solid Tumors; RR, response
rate.
were retrospectively collected for these patients, evaluated commonly every 4 weeks for sero-
logic PSA response and as clinically indicated for imaging assessment [21, 22]. In clinical prac-
tice a clinical deterioration and/or radiologic evidence of PD was sufficient to establish
enzalutamide discontinuation as well as PSA increase associated with therapy interruption sec-
ondary to unacceptable toxicity or death.
Statistical Analysis
Data were summarized by frequency for categorical variables and by median and range for
continuous variables. As baseline PSA value, pre-therapy NLR value, NLR 4 weeks and baseline
LDH were not normal distributed, they were log transformed.
Association between categorical variables was assessed using the Fisher’s exact test, when
appropriate. Progression-free survival (PFS) was calculated from the start of therapy with enza-
lutamide until disease progression or last follow-up. Patients who died without progression
were censored at the time of death. Overall survival (OS) was calculated from the start of ther-
apy until death. Patients lost to follow-up were censored at the time of last contact. The
Kaplan–Meier method was used to estimate PFS and OS. The Cox proportional hazard regres-
sion were used to compare survival between groups of patients on the basis of the NLR ratio.
After univariate analysis, a multivariate analysis was carried out by Cox regression model and
included the following variables:
• Eastern Cooperative Oncology Group (ECOG) performance status,
• visceral disease including lung, liver, brain, and bone metastases (present vs. absent),
• baseline PSA value,
• pre-therapy NLR value,
• change in NLR.
In multivariate analysis, we compared Bayesian Information Criterion (BIC) for a model
with and a model without the pre-therapy NLR. As BIC for the model without pre-therapy
NLR was lower than the model with pre-therapy NLR, it was dropped from the final model.
Patients who did not survive 4 weeks (or 12 weeks) were excluded from the analysis related to
change in NLR. Differences were considered statistically significant when P<0.05. All statistical
analyses were carried out with SAS statistical software, version 9.3 (SAS Institute, Cary, NC).
Results
Patient characteristics
This study included 193 consecutive CRPC patients from 9 centers. Median age was 73.1 years
(range 42.8–90.7). Median follow-up was 11.7 months (range 0.5–27.4). The median baseline
NLR was 3.2. One hundred and five patients (54.4%) had baseline NLR>3. At study entry, 58
patients (30.1%) had visceral metastases (including liver, lung, bone, and brain sites) and 112
(58.3%) had multiple metastatic sites. Sixty-seven patients (35.1%) had received two or more
therapeutic lines. Baseline characteristics did not significantly differ according to baseline
NLR<3 or3 (S1 Table).
NLR and clinical outcome
At the time of analysis, 149 (77.2%)of the193 patients had progressive disease, and 106 (54.9%)
had died. The median PFS was 4.8 months (95% CI 3.7–6.0), and the median OS was 13.9
Neutrophil to Lymphocyte Ratio and Enzalutamide
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months (95% CI 10.1–15.9). In relation to NLR value, the median PFS was 7.4 months (95% CI
5.5–9.7) in patients with pre-therapy NLR3 and 3.2 months (95% CI 2.7–4.2) in those with
pre-therapy NLR>3 (p< 0.0001). The NLR was also associated with difference in PFS if it was
assessed after treatment had started. After 4 weeks, the median PFS was 6.2 months (95% CI
4.7–9.0) in 113 patients with NLR3and 3.0 months (95% CI 2.6–4.2) in 71 with NLR>3
(p< 0.0001). After 12 weeks, the median PFS was 9.3 months (95% CI 5.4–10.1) in 77 patients
with NLR3 and 3.4 months (95% CI 2.7–4.8) in 45 with NLR>3 (p< 0.0001).
The median OS was 16.9 months (95% CI 11.2–20.9) and 10.4 months (95% CI 6.5–14.9)
(p< 0.0001) in patients with pre-therapy NLR3 or>3, respectively. After 4 weeks median
OS was 15.9 months (95% CI 11.7–20.9) in the NLR group3 and 7.1 months (95% CI 6.4–
10.4) (p< 0.0001) in those with NLR>3 (p< 0.0001). At 12 weeks, patients with NLR3
showed a median OS of 20.2 months (95% CI 15.1–21.0) compared to 8.2 months (95% CI
6.2–14.9) (p = 0.002) of the NLR>3 group.
A multivariate analysis revealed that follow-up NLR after 4 and 12 weeks’ treatment with
enzalutamide was a significant predictor of PFS with HR 1.24 (95% CI 1.07–1.42) (p = 0.003)
and HR 1.09 (95% CI 1.01–1.19) (p = 0.031), respectively. Similar results were also observed for
OS for NLR after 4 weeks: HR 1.29 (95% CI 1.10–1.51) (p = 0.001), whereas were of borderline
significance for NLR after 12 weeks: HR 1.09 (95% CI 0.99–1.20) (p = 0.079). Forest plots for
PFS and OS, are presented in Figs 1 and 2, respectively. Therneau-Gramschs test failed to find,
for PFS and OS analyses, violations of the PH assumption.
Changes in NLR and PSA response rate
We divided up the two pre-therapy NLR groups (NLR 3 or >3) on the basis of the follow-
up NLR (3 or > 3), obtaining 4 subgroups: 1) low-low (pre-therapy NLR3 and follow-up
Fig 1. Forest plot for progression-free survival.
doi:10.1371/journal.pone.0158952.g001
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NLR 3); 2) low-high (pre-therapy NLR 3 and follow-up NLR>3); 3) high–low (pre-
therapy NLR > 3 and follow-up NLR3); and 4) high–high (pre-therapy NLR > 3 and fol-
low- up NLR > 3).
Changes in NLR were correlated with PSA response rate. Tables 1 and 2 show changes in
NLR and PSA response rate at 4 and 12 weeks, respectively. The groups of patients with high-
low NLR and high-high NLR were associated with poorer PSA response rate either at 4 weeks
or 12 weeks than the group with low-low NLR. PSA response rate could be considered as a mir-
ror of the association between NLR change and clinical outcome (Tables 1 and 2).
Fig 2. Forest plot for overall survival.
doi:10.1371/journal.pone.0158952.g002
Table 1. Changes in NLR and PSA response rate at 12weeks.
PSA RR <50% >50%
No. pts (%) No. pts (%) p1 OR (95% CI)2 p2
Low-Low 18 (29.5) 40 (65.6) 1.00
Low-High 7 (11.5) 3 (4.9) 0.32 (0.07–1.44)
High-Low 11 (18.0) 8 (13.1) 0.47 (0.14–1.54)
High-High 25 (41.0) 10 (16.4) 0.0002 0.66 (0.25–1.72) 0.364
Abbreviations: PSA, prostate-speciﬁc antigen; RR, response rate; pts, patients; NLR, neutrophil to lymphocyte ratio.
1unadjusted;
2adjusted by age, ECOG PS, visceral metastases, Log PSA baseline, Log LDH baseline
doi:10.1371/journal.pone.0158952.t001
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Changes in NLR and survival
We evaluated the above-mentioned 4 subgroups for PFS and OS. The high-high group showed
a significantly worse PFS (Figs 3 and 4) and OS (Figs 5 and 6) after 4 weeks of treatment with
Table 2. Changes in NLR and PSA response rate at 4 weeks.
PSA RR <50% >50%
No. pts (%) No. pts (%) p1 OR (95% CI)2 p2
Low-Low 25 (30.1) 52 (57.1) 1.00
Low-High 7 (8.4) 3 (3.3) 0.16 (0.04–0.73)
High-Low 16 (19.3) 20 (22.0) 0.60 (0.26–1.42)
High-High 45 (54.2) 16 (17.6) <0.0001 0.27 (0.13–0.58) 0.003
Abbreviations: PSA, prostate-speciﬁc antigen; RR, response rate; pts, patients; NLR, neutrophil to lymphocyte ratio.
1unadjusted;
2adjusted by age, ECOG PS, visceral metastases, Log PSA baseline, Log LDH baseline
doi:10.1371/journal.pone.0158952.t002
Fig 3. Progression-free survival according to pre-therapy and follow-up NLR at 4 weeks of enzalutamide treatment.
doi:10.1371/journal.pone.0158952.g003
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enzalutamide [HR 2.56 (95% CI 1.75–3.73) (p< 0.0001) and HR 2.87 (95% CI 1.82–4.53)
(p< 0.0001), respectively] and this was further confirmed in the NLR analysis performed after
12 weeks [HR 2.85 (95% CI 1.94–4.20) (p< 0.0001) and HR 3.02 (95% C1.93–4.72)
(p< 0.0001), respectively]. The high-low group characterized by a significantly poorer OS at 4
weeks [HR 1.95 (95% CI 1.12–3.40) (p = 0.018)] than the low-low group, while patients with
low-high NLR had a worse PFS after 12 weeks than low-low group [HR 2.04 (95% CI 1.10–
3.80) (p = 0.024)] (Table 3). A doubling of the NLR at 4 weeks, compared with baseline NLR,
increased the hazard of death/recurrence by about 25%, adjusted for all other factors.
Discussion
The present study evaluated NLR as a potential biomarker in men with CRPC treated with
enzalutamide, and confirmed the role of inflammation in prostate carcinogenesis, disease pro-
gression, CRPC development and resistance to treatment [22]. In recent years, numerous in
vitro and in vivo studies have suggested that there may be crosstalk among tumor cells, the
microenvironment and inflammatory cells in PC have suggested a cross-talk among tumor
cells, the microenvironment and inflammatory cells in PC [23–25]. The involvement of the
host’s immune system in all stages of PC has been confirmed by the increased production of
Fig 4. Progression-free survival according to pre-therapy and follow-up NLR at 12 weeks of enzalutamide treatment.
doi:10.1371/journal.pone.0158952.g004
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some cytokines including interleukin (IL)-1, IL-4 and IL-6, macrophage inhibitory cytokine 1
[26–29] and, recently, by the altered expression of modulator genes of the immune system
[30]. Ross et al.’s prospective study developed a whole-blood RNA transcript-based prognostic
model of CRPC patients [30] that included upregulated genes (C1QA, TIMP1 and CDKN1A)
known to be involved in the differentiation of monocytes to macrophages and downregulated
genes (ABL2, ITGAL and SEMA4D) that control T-cell motility and activity. Systemic inflam-
mation, fibrinogen, IL-6, and C-reactive protein levels have also been hypothesized as prognos-
tic and predictive biomarkers in PC, albeit with conflicting results [31–33]. Furthermore, the
platelet to lymphocyte ratio (PLR) been also assessed in PC patients as biomarkers of outcome
and resistance to therapy [12–16, 34].
NLR is believed to reflect the equilibrium between innate (neutrophil) and adaptive (lym-
phocyte) immune response. Its association with higher serum PSA levels observed in our study
may indicate an impairment of the adaptive host’s capacity to regulate inflammation. We used
3 as a threshold for NLR, classifying patients with NLR>3 as having a ‘high’ ratio and those
with NLR3 as having a ‘low’ ratio. Using this cut-off we confirmed the strong association
between NLR and PSA response, previously reported in other studies in PC patients treated
with cabazitaxel and abiraterone [15, 16].
Fig 5. Overall survival according to pre-therapy and follow-up NLR at 4 weeks of enzalutamide treatment.
doi:10.1371/journal.pone.0158952.g005
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The majority of previous studies focused only on pre-therapy NLR values in PC patients,
whereas we also assessed the prognostic impact of NLR during treatment. A change in NLR
may reflect the dynamic alterations of balance among host inflammatory response, immune
response, and the effect of treatment. The results of our study were not compromised by the
problem of data interpretation relating to the concomitant use of corticosteroids, which are
used in combination with abiraterone. Then, our results, in terms of prediction, can only be
applied to studies similar to this one, but not to those with concomitant use of corticosteroids.
Steroids often alter NLR value by reducing the number of lymphocytes, redistributing them in
other body compartments (e.g. spleen, lymph nodes, and bone marrow) and accelerating the
release of neutrophils from the bone marrow into the circulation. Consequently, patients on
corticosteroids usually have a higher NLR, as reported by Lorente et al. [15] who demonstrated
that NLR prognostic value was independent of the prior use of corticosteroids.
Our study revealed the importance of evaluating NLR values before and during treatment
because patients in the high-high risk group (pre-therapy and follow-up NLR> 3) had a
markedly worse prognosis, (Figs 3 to 6), with results of the multivariate analysis that suggest
NLR after 4 weeks of enzalutamide as better predictor of OS (HR = 1.29, p = 0.001) than NLR
Fig 6. Overall survival according to pre-therapy and follow-up NLR at 12 weeks of enzalutamide treatment.
doi:10.1371/journal.pone.0158952.g006
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after 12 weeks (HR = 1.09, p = 0.079) (Table 3). However, when dividing patients for subgroups
according to baseline and follow-up NLR, a persistent NLR>3 was able to strongly predict the
clinical outcome after either 4 or 12 weeks (Table 3, Figs 3 to 6).
Although follow-up NLR has been investigated in other urological malignancies as a rele-
vant prognostic factor [35, 36], we analyzed NLR at two different treatment times, with compa-
rable results. In conclusion, the results from the present study would seem to indicate that a
persistent increase in NLR during enzalutamide has both a prognostic and predictive value in
patients with CRPC. Currently, the identification of non-invasive markers in PC patients
treated with new hormonal drugs, such as enzalutamide, is the object of much of the transla-
tional research carried out into this area, and NLR could, like PSA, prove to be an important
factor to monitor treatment in PC patients. It must, however, be pointed out that our work is
somewhat limited by the retrospective nature of the analysis, the sample size, the absence of
external validation, and the heterogeneity of previous lines of therapy administered. An inde-
pendent validation of our findings is thus needed in a larger prospective study.
Supporting Information
S1 Table. Clinical Data Neutrophil to lymphocyte ratio and Enzalutamide Final.
(XLS)
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Table 3. Change in NLR and survival.
PFS OS
4 weeks n.
pts
n.
events
Median value (months)
(95% CI)
HR (95% CI) p n.
events
Median value (months)
(95% CI)
HR (95% CI) p
Low-Low 77 56 9.0 (5.9–10.1) 1.00 39 20.2 (13.0–21.0) 1.00
Low-
High
10 7 6.2 (2.0–14.0) 1.32 (0.60–
2.92)
0.491 5 9.9 (6.2-nr) 1.75 (0.68–
4.51)
0.249
High-
Low
36 26 4.4 (2.8–6.7) 1.50 (0.94–
2.38)
0.085 19 13.9 (6.5–17.2) 1.95 (1.12–
3.40)
0.018
High-
High
61 51 2.7 (2.4–4.0) 2.56 (1.75–
3.73)
<0.0001 36 6.8 (5.8–14.6) 2.87 (1.82–
4.53)
<0.0001
PFS OS
12 weeks n.
pts
n.
events
Median value (months)
(95% CI)
HR (95% CI) p n.
events
Median value (months)
(95% CI)
HR (95% CI) p
Low-Low 58 38 9.3 (6.1–10.3) 1.00 29 20.2 (13.0–21.0) 1.00
Low-
High
10 8 5.1 (2.7–7.4) 2.04 (1.10–
3.80)
0.024 4 8.7 (6.6-nr) 0.99 (0.43–
2.25)
0.980
High-
Low
19 11 4.6 (2.8–6.7) 1.38 (0.82–
2.32)
0.229 4 17.2 (10.4–21.0) 1.18 (0.61–
2.29)
0.613
High-
High
35 27 2.8 (2.5–4.0) 2.85 (1.94–
4.20)
<0.0001 21 6.7 (5.7–10.6) 3.02 (1.93–
4.72)
<0.0001
Abbreviations: NLR, neutrophil to lymphocyte ratio; pts, patients; PFS, progression free survival; OS, overall survival; HR; hazard ratio; CI, conﬁdence
interval; nr, not reached.
doi:10.1371/journal.pone.0158952.t003
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